News

ODU, EVMS, Sentara Name Partnership Executive Director

Kevin Leslie has been named executive director of the new Hampton Roads Biomedical Research Consortium (HRBRC), a partnership between Old Dominion University, Eastern Virginia Medical School (EVMS) and Sentara Healthcare.

Recently approved by Gov. Ralph Northam and the General Assembly, the HRBRC aims to strengthen the relationship among the three institutions and to jump start more research collaboration as well as to ultimately generate health-care improvements in Hampton Roads, making it more efficient and less expensive.

“The state has commissioned a study to recommend the optimal structure for our partnership. But for now, the consortium’s first order of business is to mine the region’s vast collection of health-care data – stripped of personal information,” said Morris Foster, Old Dominion’s vice president for research who helped establish the framework for the consortium. “The resulting algorithms and applications could produce extensive benefits for our region, including wearable devices to monitor health and more pinpointed recommendations for patients.”

Leslie was previously the associate director of VCU Ventures, a division at Virginia Commonwealth University that helps faculty and staff launch startup companies with an eye to innovation in health care. He received his Ph.D. in biophysics from VCU and has worked as a senior scientist in the private sector.

“Kevin knows the biotech ecosystem in the commonwealth, and he’s well-versed in sources of funding opportunities, both on the public and private sides,” Foster said. “Under his direction, the consortium stands poised to build the biotech sector in Hampton Roads and catalyze more innovation.”

Dr. Jordan Asher, Sentara’s chief physician executive, expressed his appreciation for the commonwealth’s support and added: “We are excited to collaborate with ODU and EVMS in this new endeavor to advance research in the Hampton Roads region that will improve the health of our communities.”

“We welcome Kevin to the region and are excited to collaborate with him and our partners in the HRBRC to advance biohealth development and innovation,” said William Wasilenko, vice dean for research at EVMS.

Leslie believes the region as a whole could see a big economic-development boost.

“The HRBRC embodies what drives and excites me: the challenges of a startup, the pursuit of health equity, community building and working with diverse and talented people,” Leslie said. “The foundational pieces of a world-class pipeline are in place. Now, we finally have the opportunity to coordinate them in earnest.

“We’re going to advance science and medicine while holistically strengthening Hampton Roads, and I’m honored to be a part of it.”

According to Foster, Old Dominion’s faculty will benefit from increased opportunities for collaboration with colleagues at EVMS and Sentara and will become more competitive for NIH grants.

“Graduate students will also gain valuable experience in projects that will strengthen their dissertations and their scientific potential after they leave ODU,” he said.

Recent News

07/23/2026

Activation Capital Expands the Bio+Tech Center, Doubling Laboratory Capacity to Strengthen Virginia’s Life Sciences Entrepreneurship and Innovation Ecosystem

Activation Capital, the operating name of the Virginia Biotechnology Research Partnership Authority, today announced an expansion of its Bio+Tech Center to support the continued growth of life sciences entrepreneurship across the region. Activation Capital’s Bio+Tech Center is a life sciences incubator located within the Virginia Bio+Technology Research Park. Serving as both a physical and programmatic

07/22/2026

Epidarex Announces Leadership Appointments

With the launch of our latest fund, Epidarex Capital IV, LP, we are pleased to announce several promotions. As we continue to grow and deepen our impact across the US and UK life science ecosystems, recognizing and elevating exceptional talent within our team is a vital part of that journey. These transitions reflect our continued

07/22/2026

Phlow Corp. Appoints Sripathy Venkatraman, Ph.D, As Chief Scientific Officer

Phlow Corp., a U.S.-based advanced pharmaceutical contract development and manufacturing organization (CDMO), dedicated to strengthening the nation’s pharmaceutical supply chain and protecting America’s medicine cabinet, today announced the appointment of Sripathy Venkatraman, Ph.D., MBA, as Chief Scientific Officer. Venkatraman brings more than 25 years of experience in pharmaceutical development, process chemistry, manufacturing, and scientific leadership. He